vimarsana.com

Page 14 - நிறுவனம் பதிவு அறிக்கை ஆன் வடிவம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MEDIROM Healthcare Technologies Inc  Announces Closing of $12,000,000 Initial Public Offering

Press release content from Globe Newswire. The AP news staff was not involved in its creation. MEDIROM Healthcare Technologies Inc. Announces Closing of $12,000,000 Initial Public Offering MEDIROM Healthcare Technologies Inc.December 31, 2020 GMT NEW YORK, Dec. 31, 2020 (GLOBE NEWSWIRE) MEDIROM Healthcare Technologies Inc. (NasdaqCM:MRM), a holistic healthcare company from Japan (the “Company”), announced today that it has closed its previously announced initial public offering of 800,000 ADSs at a price to the public of US$15.00 per share. Each ADS represents one share of the Company’s common stock. After underwriting discounts and offering expenses, the Company expects to receive net proceeds of approximately US$7.8 million.

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111 2B Global Metastatic Cancer Market - Press Release

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111 2B Global Metastatic Cancer Market - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111 2B Global Metastatic Cancer Market

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards producing commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen. The Company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth US$111.2 Billion by 2027, according to current analysis by Emergen Research.

AmeriCann, Inc : AmeriCann Announces Record Revenue for 2020

AmeriCann, Inc.: AmeriCann Announces Record Revenue for 2020 Company Reported Full Fiscal Year 2020 Financial Results BOSTON, MA / ACCESSWIRE / December 22, 2020 / AmeriCann, Inc. (OTCQB:ACAN), a cannabis company that develops state-of-the-art cultivation, processing and product manufacturing facilities, announced its financial results for the 12 months ended September 30, 2020. 2020 Financial Highlights and Recent Developments The Company achieved record revenue for its fiscal year ending September 2020. AmeriCann s revenue increased by $796,520 from 2019 to 2020. The Company s operating revenue increased in every quarter for its fiscal year ending September 2020. AmeriCann s operating revenue from Building 1, the completed first phase of the Company s Massachusetts Cannabis Center ( MCC ), increased 178% for the quarter that ended September 30, 2020 from the prior quarter.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.